| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
144,135,000 |
| Market
Cap: |
9.24(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,202,818 |
| 52
Week Range: |
$29.84 - $68.15 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1083 |
| Guru Rank Value : 0 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,808 |
151,714 |
421,299 |
921,110 |
| Total Sell Value |
$6,239,448 |
$8,287,699 |
$19,543,609 |
$50,719,794 |
| Total People Sold |
8 |
8 |
10 |
11 |
| Total Sell Transactions |
19 |
33 |
73 |
127 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-12-08 |
4 |
S |
$65.96 |
$68,730 |
D/D |
(1,042) |
50,660 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2025-12-08 |
4 |
OE |
$39.13 |
$40,773 |
D/D |
1,042 |
51,702 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-12-02 |
4 |
S |
$63.89 |
$140,558 |
D/D |
(2,200) |
140,610 |
|
-3% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-12-02 |
4 |
OE |
$10.60 |
$23,320 |
D/D |
2,200 |
142,810 |
|
- |
|
| Henderson John T |
Director |
• • – |
2025-12-02 |
4 |
S |
$63.90 |
$559,125 |
D/D |
(8,750) |
74,578 |
|
-3% |
|
| Henderson John T |
Director |
• • – |
2025-12-02 |
4 |
OE |
$10.00 |
$87,500 |
D/D |
8,750 |
83,328 |
|
- |
|
| Harrington Robert Arthur |
Director |
• • – |
2025-12-01 |
4 |
S |
$66.80 |
$143,620 |
D/D |
(2,150) |
18,542 |
|
1% |
|
| Kaye Edward M. Md |
Director |
• • – |
2025-12-01 |
4 |
S |
$66.72 |
$1,872,430 |
D/D |
(28,064) |
9,977 |
|
1% |
|
| Kaye Edward M. Md |
Director |
• • – |
2025-12-01 |
4 |
OE |
$12.40 |
$384,994 |
D/D |
28,064 |
38,041 |
|
- |
|
| Parshall B Lynne |
Director |
• • – |
2025-11-19 |
4 |
S |
$64.73 |
$323,650 |
D/D |
(5,000) |
22,933 |
|
-1% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-11-18 |
4 |
S |
$66.45 |
$146,190 |
D/D |
(2,200) |
140,610 |
|
1% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-11-18 |
4 |
OE |
$10.60 |
$23,320 |
D/D |
2,200 |
142,810 |
|
- |
|
| Hessekiel Jeffrey |
Chief Legal & Admin Officer |
• • – |
2025-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
87,297 |
87,297 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2025-11-11 |
4 |
S |
$65.08 |
$336,789 |
D/D |
(5,175) |
9,977 |
|
1% |
|
| Kaye Edward M. Md |
Director |
• • – |
2025-11-11 |
4 |
OE |
$9.66 |
$49,991 |
D/D |
5,175 |
15,152 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-11-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
356,108 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-11-04 |
4 |
S |
$59.55 |
$136,667 |
D/D |
(2,295) |
140,610 |
|
-10% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-11-04 |
4 |
OE |
$10.60 |
$24,327 |
D/D |
2,295 |
142,905 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-10-30 |
4 |
S |
$62.86 |
$314,300 |
D/D |
(5,000) |
358,108 |
|
-5% |
|
| Wierenga Wendell |
Director |
• • – |
2025-10-27 |
4 |
S |
$58.68 |
$256,725 |
D/D |
(4,375) |
32,444 |
|
-9% |
|
| Wierenga Wendell |
Director |
• • – |
2025-10-27 |
4 |
OE |
$10.00 |
$43,750 |
D/D |
4,375 |
36,819 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-10-21 |
4 |
S |
$58.22 |
$122,553 |
D/D |
(2,105) |
140,610 |
|
-14% |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2025-10-21 |
4 |
OE |
$10.60 |
$22,313 |
D/D |
2,105 |
142,715 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2025-10-16 |
4 |
S |
$60.03 |
$300,150 |
D/D |
(5,000) |
363,108 |
|
-11% |
|
| Wierenga Wendell |
Director |
• • – |
2025-10-15 |
4 |
A |
$62.80 |
$6,217 |
D/D |
99 |
32,444 |
|
- |
|
947 Records found
|
|
Page 1 of 38 |
|
|
1.54 (2.35%) 
